The FDA has granted Breakthrough Therapy Designation to Johnson & Johnson's cancer drug, JNJ-73841937, for the treatment of advanced head and neck cancer.

This article provides a roundup of recent dividend declarations from various companies including Halliburton, AbbVie, Johnson & Johnson, and Delta Air Lines.

Johnson & Johnson is reportedly exploring the sale of its orthopedics business, a move that could reshape its medical device portfolio.

Johnson & Johnson has secured approval for monthly dosing of its drug Rybrevant Faspro, offering a new treatment option.

Johnson & Johnson is exploring the sale of its orthopedics unit, a move that could fetch more than $20 billion.

Johnson & Johnson is reportedly exploring a potential $20 billion sale of its orthopedics unit.

Johnson & Johnson plans to construct a new $1 billion cell and gene therapy manufacturing facility in Pennsylvania, expanding its production capabilities.

Financial commentator Jim Cramer shares his latest opinions on several major stocks, including Procter & Gamble, Norfolk Southern, and Johnson & Johnson, offering insights into their performance and market standing.

Bloomberg News reports that Johnson & Johnson is considering the sale of its orthopedics unit, a move that could be valued at $20 billion.

An analysis compares Verizon and Johnson & Johnson to determine which dividend hike winner is the better investment.

AC Immune announced that its partner Johnson & Johnson has paused enrollment in a mid-stage clinical trial for an Alzheimer’s drug.